Health Technology Assessment
A fair and efficient distribution of financial means is of increasing importance in healthcare systems with limited economic resources.
Health Technology Assessment refers to the systematic and evidence-based evaluation of medical procedures and technologies regarding their effects on the Healthcare system. Dimensions of these evaluations include medical economic, ethical and social aspects. In radiology, these refer mainly to diagnostic procedures but may also include therapeutic aspects and are applied to both high- and low-income countries. Goal of our group is to achieve an efficient distribution of resources in the healthcare systems and accelerate the translation of new and innovative technologies such as modern imaging technologies and use of Artificial Intelligence in the clinics.
Dr. Dr. Egon Burian, MD, DMD, MBA
Dr. Florian Gassert, MD, BSc
Dr. Felix Hofmann
Dr. Claudio von Schacky
Alexander Marka, MD
Lisa Steinhelfer, MD
Ludwigs-Maximilians Universität München, Prof. Dr. Johannes Rübenthaler
Universität Heidelberg, PD Dr. Matthias Frölich
Center for Intelligent Imaging, UCSF
Siemens Healthineers
Burian E, Palla B, Callahan N, Pyka T, Wolff C, von Schacky CE, Schmid A, Froelich MF, Rübenthaler J, Makowski MR, Gassert FG. Comparison of CT, MRI, and F-18 FDG PET/CT for initial N-staging of oral squamous cell carcinoma: a cost-effectiveness analysis. Eur J Nucl Med Mol Imaging. 2022 May 24. doi: 10.1007/s00259-022-05843-4. Epub ahead of print. PMID: 35606526.
Gassert FG, Rübenthaler J, Cyran CC, Rink JS, Schwarze V, Luitjens J, Gassert FT, Makowski MR, Schoenberg SO, Mayerhoefer ME, Tamandl D, Froelich MF. 18F FDG PET/MRI with hepatocyte-specific contrast agent for M staging of rectal cancer: a primary economic evaluation. Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3268-3276. doi: 10.1007/s00259-021-05193-7. Epub 2021 Mar 9. PMID: 33686457; PMCID: PMC8426298
Gassert F, Schnitzer M, Kim SH, Kunz WG, Ernst BP, Clevert DA, Nörenberg D, Rübenthaler J, Froelich MF. Comparison of Magnetic Resonance Imaging and Contrast-Enhanced Ultrasound as Diagnostic Options for Unclear Cystic Renal Lesions: A Cost-Effectiveness Analysis. Ultraschall Med. 2021 Aug;42(4):411-417. English. doi: 10.1055/a-1110-7172. Epub 2020 Feb 12. PMID: 32052386
Schnitzer ML, Froelich MF, Gassert FG, Huber T, Gresser E, Schwarze V, Nörenberg D, Todica A, Rübenthaler J. Follow-Up 18F-FDG PET/CT versus Contrast-Enhanced CT after Ablation of Liver Metastases of Colorectal Carcinoma-A Cost-Effectiveness Analysis. Cancers (Basel). 2020 Aug 27;12(9):2432. doi: 10.3390/cancers12092432. PMID: 32867107; PMCID: PMC7565889
Runtemund J, Rübenthaler J, von Münchhausen N, Ingenerf M, Grawe F, Biechele G, Gassert FG, Tollens F, Rink J, Cecatka S, Schmid-Tannwald C, Froelich MF, Clevert DA, Schnitzer ML. Diagnostic Workup for Patients with Solid Renal Masses: A Cost-Effectiveness Analysis. Cancers (Basel). 2022 Apr 29;14(9):2235. doi: 10.3390/cancers14092235. PMID: 35565365; PMCID: PMC9104211
Gassert FG, Ziegelmayer S, Luitjens J, Gassert FT, Tollens F, Rink J, Makowski MR, Rübenthaler J, Froelich MF. Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis. Eur Radiol. 2022 Apr;32(4):2448-2456. doi: 10.1007/s00330-021-08356-0. Epub 2021 Nov 27. PMID: 34837511; PMCID: PMC8921086
Ziegelmayer S, Graf M, Makowski M, Gawlitza J, Gassert F. Cost-Effectiveness of Artificial Intelligence Support in Computed Tomography-Based Lung Cancer Screening. Cancers (Basel). 2022 Mar 29;14(7):1729. doi: 10.3390/cancers14071729. PMID: 35406501; PMCID: PMC8997030.
Group leader
